Serina Therapeutics Appoints Dr. Jay Venkatesan to its Board of Directors
Serina Therapeutics (NYSE American: SER) has appointed Dr. Jay Venkatesan to its Board of Directors. Dr. Venkatesan brings extensive experience in biotechnology investment and company building, most recently serving as Chairman, President, and CEO of Angion Biomedica until its 2023 merger with Elicio Therapeutics.
His notable achievements include co-founding Alpine Immune Sciences, which was acquired by Vertex Pharmaceuticals for $4.9 billion in May 2024. Dr. Venkatesan's background includes founding Ayer Capital, a healthcare investment fund, and holding positions at Brookside Capital and McKinsey & Co.
As part of this transition, Serina's co-founder Dr. Milton Harris will become Director Emeritus and Chair of the company's Scientific Advisory Board (SAB), continuing to provide guidance for the company's research and development efforts.
Serina Therapeutics (NYSE American: SER) ha nominato il Dr. Jay Venkatesan nel suo Consiglio di Amministrazione. Il Dr. Venkatesan porta con sé un'ampia esperienza negli investimenti in biotecnologia e nella creazione di aziende, avendo recentemente ricoperto il ruolo di Presidente, Amministratore Delegato e CEO di Angion Biomedica fino alla sua fusione nel 2023 con Elicio Therapeutics.
I suoi risultati notevoli includono la co-fondazione di Alpine Immune Sciences, acquisita da Vertex Pharmaceuticals per 4,9 miliardi di dollari a maggio 2024. Il background del Dr. Venkatesan comprende la fondazione di Ayer Capital, un fondo di investimento nel settore della salute, e posizioni presso Brookside Capital e McKinsey & Co.
Come parte di questa transizione, il co-fondatore di Serina, il Dr. Milton Harris, diventerà Direttore Emerito e Presidente del Consiglio Consultivo Scientifico dell'azienda (SAB), continuando a fornire indicazioni per gli sforzi di ricerca e sviluppo dell'azienda.
Serina Therapeutics (NYSE American: SER) ha nombrado al Dr. Jay Venkatesan en su Junta Directiva. El Dr. Venkatesan aporta una amplia experiencia en inversión en biotecnología y en la creación de empresas, habiendo servido más recientemente como Presidente, Director Ejecutivo y CEO de Angion Biomedica hasta su fusión en 2023 con Elicio Therapeutics.
Sus logros notables incluyen la co-fundación de Alpine Immune Sciences, que fue adquirida por Vertex Pharmaceuticals por 4.9 mil millones de dólares en mayo de 2024. El historial del Dr. Venkatesan incluye la fundación de Ayer Capital, un fondo de inversión en salud, y puestos en Brookside Capital y McKinsey & Co.
Como parte de esta transición, el cofundador de Serina, el Dr. Milton Harris, se convertirá en Director Emérito y Presidente del Consejo Asesor Científico de la empresa (SAB), continuando para proporcionar orientación para los esfuerzos de investigación y desarrollo de la empresa.
세리나 테라퓨틱스 (NYSE American: SER)는 제이 벵카테산 박사를 이사회에 임명했습니다. 벵카테산 박사는 최근 2023년 엘리시오 테라퓨틱스와의 합병 전까지 앵기온 바이오메디카의 회장, 사장 및 CEO로 재직하며 생명공학 투자 및 기업 건설 분야에서 광범위한 경험을 쌓았습니다.
그의 주목할 만한 성과 중 하나는 앨파인 면역 과학을 공동 설립한 것으로, 이는 2024년 5월 49억 달러에 버텍스 파마슈티컬스에 인수되었습니다. 벵카테산 박사는 헬스케어 투자 펀드인 에이어 캐피탈을 설립하고 브룩사이드 캐피탈 및 맥킨지 & Co.에서 직책을 맡은 경력이 있습니다.
이 전환의 일환으로 세리나의 공동 창립자인 밀턴 해리스 박사는 명예 이사로 임명되고 회사의 과학 자문 위원회(SAB) 의장이 되어 회사의 연구 및 개발 노력에 대한 지침을 계속 제공할 것입니다.
Serina Therapeutics (NYSE American: SER) a nommé le Dr. Jay Venkatesan à son Conseil d'Administration. Le Dr. Venkatesan apporte une vaste expérience dans l'investissement en biotechnologie et la création d'entreprises, ayant récemment occupé le poste de Président, Directeur Général et CEO d'Angion Biomedica jusqu'à sa fusion en 2023 avec Elicio Therapeutics.
Parmi ses réalisations notables, on trouve la co-fondation d'Alpine Immune Sciences, qui a été acquise par Vertex Pharmaceuticals pour 4,9 milliards de dollars en mai 2024. Le parcours du Dr. Venkatesan inclut la fondation d'Ayer Capital, un fonds d'investissement en santé, ainsi que des postes chez Brookside Capital et McKinsey & Co.
Dans le cadre de cette transition, le co-fondateur de Serina, le Dr. Milton Harris, deviendra Directeur Émérite et Président du Conseil Consultatif Scientifique de l'entreprise (SAB), continuant ainsi à fournir des conseils pour les efforts de recherche et développement de l'entreprise.
Serina Therapeutics (NYSE American: SER) hat Dr. Jay Venkatesan in seinen Vorstand berufen. Dr. Venkatesan bringt umfangreiche Erfahrungen in der Biotechnologie-Investitionen und Unternehmensgründung mit, zuletzt als Vorsitzender, Präsident und CEO von Angion Biomedica bis zur Fusion mit Elicio Therapeutics im Jahr 2023.
Zu seinen bemerkenswerten Leistungen gehört die Mitgründung von Alpine Immune Sciences, das im Mai 2024 von Vertex Pharmaceuticals für 4,9 Milliarden Dollar übernommen wurde. Dr. Venkatesans Hintergrund umfasst die Gründung von Ayer Capital, einem Gesundheitsinvestitionsfonds, sowie Positionen bei Brookside Capital und McKinsey & Co.
Im Rahmen dieses Übergangs wird Dr. Milton Harris, Mitbegründer von Serina, zum Ehrenvorstand und Vorsitzenden des wissenschaftlichen Beratungsausschusses (SAB) des Unternehmens ernannt und wird weiterhin Leitlinien für die Forschungs- und Entwicklungsanstrengungen des Unternehmens bereitstellen.
- Appointment of experienced biotech leader with successful M&A track record
- New director's involvement in $4.9B Alpine Immune Sciences acquisition by Vertex
- Strategic expertise in corporate development and capital markets
- None.
HUNTSVILLE, AL, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, today announced the appointment of Jay Venkatesan, MD, MBA, to its Board of Directors. Dr. Venkatesan brings deep expertise in biotechnology investment, company building, and strategic growth, having successfully led and advised multiple biopharma companies through pivotal stages of development, including high-profile mergers and acquisitions.
Dr. Venkatesan most recently served as Chairman, President, and CEO of Angion Biomedica until its merger with Elicio Therapeutics in 2023. He currently serves as a Board Director at Elicio Therapeutics. Previously, he was President and Board Director of Alpine Immune Sciences, which he co-founded as a Managing Partner of Alpine BioVentures. Alpine Immune Sciences was acquired by Vertex Pharmaceuticals for
“Jay’s extensive leadership experience in biotechnology, particularly in corporate strategy, business development, and capital markets, makes him an invaluable addition to Serina’s Board,” said Steve Ledger, CEO of Serina Therapeutics. “His track record in advancing innovative therapies and successfully guiding companies through transformational transactions aligns with our mission to develop best-in-class therapeutics. We look forward to leveraging his insights as we advance our pipeline and explore strategic growth opportunities for our platform.”
Dr. Venkatesan has a distinguished career spanning investment and operational leadership roles. Before Alpine, he founded and managed Ayer Capital, a global healthcare investment fund. Earlier in his career, he was a director at Brookside Capital, a division of Bain Capital, where he co-managed healthcare investments. He also held roles as a venture investor with Patricof & Co. Ventures (now Apax Partners) and as a consultant at McKinsey & Co.
Dr. Venkatesan holds an M.D. from the University of Pennsylvania School of Medicine and an M.B.A. from the Wharton School of the University of Pennsylvania. He earned his B.A. from Williams College.
“I am excited to join the Board of Serina Therapeutics at such a dynamic time for the company,” said Dr. Venkatesan. “Serina’s innovative approach to drug development, leveraging its proprietary POZ polymer technology, holds great promise in addressing unmet needs across multiple therapeutic areas. I look forward to contributing to the company’s continued success and helping guide its strategic vision.”
Serina’s co-founder, Dr. Milton Harris, will assume the role of Director Emeritus and will serve as Chair of the company’s Scientific Advisory Board (SAB). Dr. Harris has played an instrumental role in the development of Serina’s POZ Platform, providing leadership and scientific expertise that have shaped the company’s pipeline and clinical development. In his new role, he will provide continued guidance to Serina’s research and development efforts.
About Serina Therapeutics
Serina is a clinical-stage biotechnology company developing a pipeline of wholly owned drug product candidates to treat neurological diseases and other indications. Serina’s POZ Platform™ provides the potential to improve the integrated efficacy and safety profile of multiple modalities including small molecules, RNA-based therapeutics and antibody-based drug conjugates (ADCs). Serina is headquartered in Huntsville, Alabama on the campus of the HudsonAlpha Institute of Biotechnology.
For more information, please visit https://serinatherapeutics.com.
Cautionary Statement Regarding Forward-Looking Statement
This release contains forward-looking statements within the meaning of federal securities laws. These statements are based on management’s current expectations, plans, beliefs or forecasts for the future, and are subject to uncertainty and changes in circumstances. Any express or implied statements in this press release that are not statements of historical fact, including statements about the potential of Serina’s POZ polymer technology, are forward-looking statements that involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things discussed in the company’s Annual Report on Form 10-K for the year ended December 31, 2023, the company’s Current Report on Form 8-K that was filed with the SEC on April 1, 2024, and the company’s other periodic reports and documents filed from time to time with the SEC. The information contained in this release is as of the date hereof, and Serina assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.
For inquiries, please contact:
Stefan Riley
sriley@serinatherapeutics.com
(256) 327-9630
FAQ
Who is Dr. Jay Venkatesan and what is his new role at Serina Therapeutics (SER)?
What major transaction was Dr. Venkatesan involved with before joining Serina (SER)?
What changes are happening to Dr. Milton Harris's role at Serina Therapeutics (SER)?
What is Dr. Venkatesan's educational background and previous experience?
